Pre-earnings options volume in Arcutis Biotherapeutics is normal with calls leading puts :. Implied volatility suggests the market is anticipating a move near 12.9%, or 0c, after results are released. Median move over the past eight quarters is 6.1%.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis Biotherapeutics announces the JCAD published outcomes of ZORYVE
- Arcutis Biotherapeutics Inc (ARQT) Q1 Earnings Cheat Sheet
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
- Arcutis Biotherapeutics Welcomes New CFO David Topper